Use the hyperlinks, where available to access additional clinical trial information.
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Trans Tasman Radiation Oncology Group (TROG)
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
This trial will test the hypothesis that the addition of consolidation radiotherapy to darolutamide will improve the clinical outcome of patients, compared to those patients receiving darolutamide alone. Patients will be randomised to receive 600mg darolutimide alone, twice daily, or in combination with local consolidative radiotherapy.